HUTCHMED (LON:HCM) Reaches New 52-Week Low – Time to Sell?

HUTCHMED (China) Limited (LON:HCM) shares reached a new 52-week low on Thursday . The company traded as low as GBX 154 and last traded at GBX 156.97, with a volume of 6823 shares traded. The stock had previously closed at GBX 157.50.

HUTCHMED Stock Performance

The company has a market cap of £1.36 billion, a PE ratio of 2.99 and a beta of 0.37. The company has a debt-to-equity ratio of 7.91, a quick ratio of 2.97 and a current ratio of 4.96. The firm’s 50 day moving average is GBX 187.32 and its 200-day moving average is GBX 204.21.

HUTCHMED Company Profile

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception, we have focused on bringing cancer drug candidates from in-house discovery to patients around the world, with our first three oncology medicines now approved marketed in China, the first of which is also marketed in the U.S.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).